Last updated August 18, 2026
Key finding
Changes in the objective parameters, ie, reductions in blood sugar level (fasting and postprandial) will be observed.
Nimba-Amalakyadi formulation compared to metformin in adults with type 2 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
Nimba-Amalakyadi formulation compared to metformin in adults with type 2 diabetes.
This study evaluated Nimba-Amalakyadi formulation compared to metformin in adults with type 2 diabetes.
Limitations were not clearly described in the extracted text.
Published in
Publication details and source links for this paper.
Punam S, Gaurav RS, Amy S. Feasibility and Comparative Efficacy of Nimba Amalakyadi Formulation Versus Metformin Tablets for Management of Type 2 Diabetes Mellitus: A Pilot Study. JMIR Research Protocols. 2026;15:e63574. doi:10.2196/63574
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Metformin, Nimba-Amalakyadi powder and Fasting Plasma Glucose (FPG), Glucose iAUC (OGTT).
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
4
Evidence pairs
300
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Metformin → Fasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Nimba-Amalakyadi powder → Fasting Plasma Glucose (FPG)
Nimba-Amalakyadi powder → Fasting Plasma Glucose (FPG)
Nimba-Amalakyadi powder → Glucose iAUC (OGTT)
Nimba-Amalakyadi powder → Glucose iAUC (OGTT)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Fasting Glucose, Metformin Therapies and Postprandial and OGTT Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
7 results
4 results
7 results
7 results
4 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 83.9 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with generally consistent results and a positive effect signal.
Limitations
Metformin Therapies may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Nimba-Amalakyadi powder for Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Nimba-Amalakyadi powder for Glucose iAUC (OGTT).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
